JP2007051159A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007051159A5 JP2007051159A5 JP2006300276A JP2006300276A JP2007051159A5 JP 2007051159 A5 JP2007051159 A5 JP 2007051159A5 JP 2006300276 A JP2006300276 A JP 2006300276A JP 2006300276 A JP2006300276 A JP 2006300276A JP 2007051159 A5 JP2007051159 A5 JP 2007051159A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- therapeutic agent
- liver cancer
- cancer according
- glypican
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
Claims (3)
- 補体依存性細胞障害活性(CDC活性)を有する抗グリピカン3抗体を有効成分として含む肝癌治療剤。
- 抗体がモノクローナル抗体である請求項1の肝癌治療剤。
- 抗体がヒト型またはキメラ化されたものである請求項1又は2のいずれかに記載の肝癌治療剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006300276A JP2007051159A (ja) | 2001-06-22 | 2006-11-06 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001189443 | 2001-06-22 | ||
JP2006300276A JP2007051159A (ja) | 2001-06-22 | 2006-11-06 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005133154A Division JP2005225892A (ja) | 2001-06-22 | 2005-04-28 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007165739A Division JP2007238632A (ja) | 2001-06-22 | 2007-06-25 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007051159A JP2007051159A (ja) | 2007-03-01 |
JP2007051159A5 true JP2007051159A5 (ja) | 2007-04-19 |
Family
ID=19028362
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003507268A Expired - Lifetime JP4281869B2 (ja) | 2001-06-22 | 2002-06-21 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2005133154A Withdrawn JP2005225892A (ja) | 2001-06-22 | 2005-04-28 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2006300276A Withdrawn JP2007051159A (ja) | 2001-06-22 | 2006-11-06 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2007165739A Pending JP2007238632A (ja) | 2001-06-22 | 2007-06-25 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2008028527A Pending JP2008120828A (ja) | 2001-06-22 | 2008-02-08 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2008228128A Expired - Lifetime JP4347402B2 (ja) | 2001-06-22 | 2008-09-05 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2009105835A Expired - Lifetime JP5596935B2 (ja) | 2001-06-22 | 2009-04-24 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003507268A Expired - Lifetime JP4281869B2 (ja) | 2001-06-22 | 2002-06-21 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2005133154A Withdrawn JP2005225892A (ja) | 2001-06-22 | 2005-04-28 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007165739A Pending JP2007238632A (ja) | 2001-06-22 | 2007-06-25 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2008028527A Pending JP2008120828A (ja) | 2001-06-22 | 2008-02-08 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2008228128A Expired - Lifetime JP4347402B2 (ja) | 2001-06-22 | 2008-09-05 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
JP2009105835A Expired - Lifetime JP5596935B2 (ja) | 2001-06-22 | 2009-04-24 | 抗グリピカン3抗体を含む細胞増殖抑制剤 |
Country Status (15)
Country | Link |
---|---|
US (3) | US20040236080A1 (ja) |
EP (3) | EP1411118B1 (ja) |
JP (7) | JP4281869B2 (ja) |
KR (3) | KR100877176B1 (ja) |
CN (2) | CN101240022B (ja) |
AT (2) | ATE407204T1 (ja) |
AU (2) | AU2002315857B2 (ja) |
CA (1) | CA2451493C (ja) |
CY (1) | CY1113854T1 (ja) |
DE (2) | DE60228721D1 (ja) |
DK (2) | DK2208784T3 (ja) |
ES (3) | ES2353335T3 (ja) |
HK (2) | HK1079547A1 (ja) |
PT (2) | PT2208784E (ja) |
WO (1) | WO2003000883A1 (ja) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
DE60228721D1 (en) * | 2001-06-22 | 2008-10-16 | Chugai Pharmaceutical Co Ltd | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper |
WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
CN100401068C (zh) * | 2002-05-23 | 2008-07-09 | 阳光溪流女子学院健康科学中心 | 肝细胞癌的诊断 |
JPWO2005023301A1 (ja) * | 2003-09-04 | 2006-11-02 | 中外製薬株式会社 | 胆管癌治療剤および検出薬 |
ATE486610T1 (de) * | 2004-07-09 | 2010-11-15 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
PT1800693E (pt) * | 2004-08-24 | 2013-08-23 | Chugai Pharmaceutical Co Ltd | Terapia adjuvante utilizando anticorpo antiglipicana |
CN101068836B (zh) * | 2004-10-26 | 2013-08-14 | 中外制药株式会社 | 糖链改变的抗磷脂酰肌醇聚糖3抗体 |
JP5620626B2 (ja) * | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
KR20080035595A (ko) | 2005-08-03 | 2008-04-23 | 마츠시타 덴끼 산교 가부시키가이샤 | 기지국 장치, 통신 단말 장치 및 멀티 캐리어 통신 방법 |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
US7723043B2 (en) * | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9670269B2 (en) * | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
PT2178921E (pt) | 2007-07-17 | 2016-03-23 | Squibb & Sons Llc | Anticorpos monoclonais contra glipicano-3 |
KR102467302B1 (ko) * | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
EP2584043A3 (en) | 2007-09-28 | 2013-10-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody having improved kinetics in plasma |
MY177564A (en) | 2007-12-05 | 2020-09-20 | Chugai Pharmaceutical Co Ltd | Anti-nr10 antibody and use thereof |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
EP3521311A1 (en) * | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20120071634A1 (en) | 2009-03-19 | 2012-03-22 | Chugai Seiyaku Kabushiki Kaisha | Antibody Constant Region Variant |
US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
EP4303236A3 (en) | 2010-11-30 | 2024-03-20 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US20120190049A1 (en) * | 2010-12-10 | 2012-07-26 | University Of Washington Through Its Center For Commercialization | Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
DK2698431T3 (da) | 2011-03-30 | 2020-11-30 | Chugai Pharmaceutical Co Ltd | Opretholdelse af antigen-bindende molekyler i blodplasma og fremgangsmåde til modifikation af immunogenicitet |
KR20140076593A (ko) | 2011-09-30 | 2014-06-20 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
CN110680920A (zh) | 2011-09-30 | 2020-01-14 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
EP2765192A4 (en) | 2011-10-05 | 2015-04-15 | Chugai Pharmaceutical Co Ltd | ANTIGEN BINDING MOLECULE FOR PROMOTING THE PLASMA CLAIR OF AN ANTIGEN COMPRISING A SACCHARIDIC CHAIN TYPE RECEPTOR BINDING DOMAIN |
SG11201405137QA (en) | 2012-02-24 | 2014-12-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
AU2013268418B2 (en) | 2012-05-30 | 2017-12-07 | Chugai Seiyaku Kabushiki Kaisha | Target-tissue-specific antigen-binding molecule |
SG11201407972RA (en) * | 2012-06-01 | 2015-01-29 | Us Health | High-affinity monoclonal antibodies to glypican-3 and use thereof |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
WO2015083764A1 (ja) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ |
CN106459959A (zh) | 2014-05-08 | 2017-02-22 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
ES2899894T3 (es) | 2014-12-19 | 2022-03-15 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-C5 y métodos de uso |
NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
CA2973771A1 (en) * | 2015-01-16 | 2016-07-21 | Minomic International Ltd. | Glypican epitopes and uses thereof |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
BR112017014067B1 (pt) | 2015-02-27 | 2021-01-12 | Chugai Seiyaku Kabushiki Kaisha | usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6 |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
US11376326B2 (en) | 2015-07-01 | 2022-07-05 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective |
DK3333192T3 (da) * | 2015-08-03 | 2021-05-31 | Cafa Therapeutics Ltd | Antistof imod glypican-3 og anvendelse deraf |
KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
CA3004438A1 (en) * | 2015-11-09 | 2017-05-18 | The Children's Hospital Of Philadelphia | Glypican 2 as a cancer marker and therapeutic target |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
KR20180091918A (ko) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
CN110214151A (zh) | 2016-11-28 | 2019-09-06 | 中外制药株式会社 | 具有可调节的配体结合活性的配体结合分子 |
WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法 |
US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
US20210206845A1 (en) | 2017-11-28 | 2021-07-08 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand-binding activity |
AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
EP3816182A4 (en) | 2018-05-30 | 2022-07-13 | Chugai Seiyaku Kabushiki Kaisha | LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY |
AU2019288733C1 (en) | 2018-06-22 | 2023-08-03 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
EA202190915A1 (ru) | 2018-10-01 | 2021-08-17 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения солидных опухолей |
AU2019366956A1 (en) | 2018-10-23 | 2021-05-20 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
EP3943108A4 (en) | 2019-03-19 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN |
WO2020246567A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド |
EP4023230A4 (en) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CLEAVAGE SITE BINDING MOLECULE |
MX2022013112A (es) | 2020-04-22 | 2023-01-16 | Dragonfly Therapeutics Inc | Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc. |
KR20230048059A (ko) | 2020-07-31 | 2023-04-10 | 추가이 세이야쿠 가부시키가이샤 | 키메라 수용체를 발현하는 세포를 포함하는 의약 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04228089A (ja) | 1990-05-15 | 1992-08-18 | Kanegafuchi Chem Ind Co Ltd | 高カルシウム血症治療・予防剤 |
EP0729976A1 (en) * | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
JP3587664B2 (ja) | 1996-10-04 | 2004-11-10 | 中外製薬株式会社 | 再構成ヒト抗hm1.24抗体 |
UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
JP4228089B2 (ja) | 1997-03-11 | 2009-02-25 | 株式会社ニコン | 過電流検知機構およびそれを用いた電子閃光装置 |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
EP1020522B1 (en) * | 1997-10-03 | 2007-09-19 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
JP3445153B2 (ja) | 1998-06-04 | 2003-09-08 | 富士通株式会社 | 電話番号一時的使用装置及び方法 |
DE60039893D1 (ja) * | 1999-08-23 | 2008-09-25 | Chugai Pharmaceutical Co Ltd | |
DE60228721D1 (en) * | 2001-06-22 | 2008-10-16 | Chugai Pharmaceutical Co Ltd | Zellproliferationsinhibitoren mit anti-glypican-3-antikörper |
-
2002
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko active IP Right Grant
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Application Discontinuation
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko active IP Right Grant
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja active Application Filing
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
-
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
- 2005-12-15 HK HK05111542A patent/HK1079547A1/xx not_active IP Right Cessation
-
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
-
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
-
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
- 2008-11-07 HK HK08112277.1A patent/HK1120522A1/xx not_active IP Right Cessation
-
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Lifetime
-
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007051159A5 (ja) | ||
LTC2567976I2 (lt) | Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui | |
LTPA2020536I1 (lt) | Nauji anti-CD38 antikūnai, skirti vėžio gydymui | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
DK3656793T3 (da) | Monoklonale antistoffer mod claudin-18 til cancerbehandling | |
LTC1620113I2 (lt) | Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui | |
IL186671A (en) | Monoclonal antibodies that bind specifically to the amyloid-cell peptide, methods of making them, pharmaceutical preparations that include them and their use in the manufacture of drugs | |
WO2010066803A3 (en) | Human antibodies against human tissue factor | |
CR9253A (es) | Fijacion de la dosificacion de anticuerpos her | |
EP2103628A4 (en) | MONOCLONAL ANTIBODY ANTI-CLAUDIN 3, AND TREATMENT AND DIAGNOSIS OF CANCER USING SUCH ANTIBODY | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
MY185647A (en) | Therapeutic agent for pruritus | |
NL1028599A1 (nl) | Verbindingen voor de behandeling van ziekten. | |
JP2008506632A5 (ja) | ||
NL1028087A1 (nl) | Sulfonamiderivaten voor de behandeling van ziekten. | |
JP2006298933A5 (ja) | ||
JP2007520565A5 (ja) | ||
WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
NL1028193A1 (nl) | Farmaceutisch werkzame verbindingen. | |
WO2004094473A3 (en) | Humanized antibodies to interferon alpha receptor-1 (ifnar-1) | |
JP2011219478A5 (ja) | ||
EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
NL1028664A1 (nl) | Sulfonamideverbindingen voor de behandeling van neurodegeneratieve ziekten. | |
NL1026203A1 (nl) | Verbindingen toepasbaar voor de behandeling van ziekten. | |
WO2008049990A3 (fr) | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |